Oklahoma Releases Medical Cannabis Patient Outcomes Report

Report Scope and Patient Population

The Oklahoma Medical Marijuana Authority report covers data from January 2024 through April 2026 and tracks outcomes for 387,214 active patients. That's a 12% increase over the 2024 baseline, making Oklahoma the fourth-largest medical program by cardholder count after California, Florida, and Pennsylvania.

OMMA aggregated anonymized patient surveys, dispensary transaction logs, and physician attestation forms filed under Oklahoma Administrative Code 310:681. The agency collected responses from 41,308 patients—a 10.7% response rate—and cross-referenced those with point-of-sale data from 1,842 licensed dispensaries.

Reported Treatment Outcomes

Seventy-three percent of surveyed patients reported symptom improvement after six months of cannabis use, with chronic pain and anxiety as the top qualifying conditions. The breakdown:

• Chronic pain: 68% of patients, 76% reported moderate-to-significant relief
• Anxiety disorders: 22% of patients, 71% reported improvement
• PTSD: 9% of patients, 69% reported symptom reduction
• Cancer-related symptoms: 4% of patients, 81% reported nausea or appetite improvement

Average monthly consumption was 2.4 ounces of flower or flower-equivalent concentrates. Patients using tinctures or edibles exclusively reported lower perceived efficacy (61% improvement rate) compared to those using flower or vaporized concentrates (78%).

Supply-Chain Bottlenecks Flagged

OMMA identified processing delays and lab-testing capacity constraints as the two biggest operational drags on the program. Cultivation license renewals took an average of 47 days in Q1 2026, up from 22 days in 2024. Staffing shortages in the compliance division drove the slowdown.

Only 14 ISO-accredited cannabis testing labs operate statewide, down from 19 in 2024 after five labs surrendered licenses citing cost pressures. Labs reported 12-to-18-day turnaround times for potency and contaminant panels—double the 2024 average. Dispensary operators told OMMA that testing delays forced them to hold inventory longer, increasing spoilage risk and shrinking margins.

Compliance Gaps and Enforcement Actions

OMMA issued 214 compliance violations and suspended 31 licenses between January 2024 and April 2026, primarily for seed-to-sale tracking failures. BioTrack THC is the mandatory traceability platform. Audits found that 18% of growers failed to log harvest batches within the required 24-hour window.

Twelve dispensaries were cited for selling untested product after lab certificates expired. OMMA didn't pursue criminal referrals but imposed administrative fines totaling $487,000. Smaller operators—those with fewer than three employees—accounted for 71% of violations, pointing to a training or resource gap.

Physician Participation and Telemedicine Trends

The number of physicians writing cannabis recommendations dropped 9% year-over-year, from 1,842 in 2024 to 1,676 in April 2026. OMMA attributed the decline to uncertainty around telemedicine rules and liability concerns after two high-profile malpractice suits involving cannabis recommendations.

Telemedicine consultations accounted for 64% of new patient certifications in 2026, up from 52% in 2024. The average telemedicine visit lasted 11 minutes. In-person evaluations ran 23 minutes. OMMA didn't assess whether visit length correlated with patient outcomes but flagged the disparity for future study.

Product-Type Preferences and Pricing Data

Flower remained the dominant product category at 61% of total sales by weight, but concentrate sales grew 22% year-over-year. Average retail prices:

• Flower: $6.80 per gram (down 14% from 2024)
• Vape cartridges: $28 per 0.5g cart (down 8%)
• Edibles: $18 per 100mg package (flat)
• Tinctures: $42 per 30mL bottle (up 6%)

Price compression in flower and concentrates reflected oversupply. With 2,214 active cultivation licenses producing an estimated 1.8 million pounds annually, the state grows well above in-state demand. Some growers told OMMA they're exploring interstate export options if federal rescheduling or SAFE Banking passage opens new channels.

Program Outlook and Recommendations

OMMA recommended five operational changes: faster license renewals, lab-capacity expansion, better seed-to-sale training, telemedicine guardrails, and a patient-registry modernization project. The agency requested $4.2 million in additional funding from the state legislature to hire 18 compliance staff and upgrade BioTrack integration with dispensary POS systems.

OMMA didn't address pending federal rescheduling or banking legislation, but the report noted that 280E tax burdens remain the top financial complaint from operators. For full context on Oklahoma's medical program structure and recent policy shifts, see the CannIntel topic hub on Oklahoma Medical Cannabis.

We'll be watching the November 2026 data release, which will cover the full calendar year and add longitudinal outcome tracking for patients who remain in the program beyond two years.